向气体皮质D介导的烧:一种针对急性和慢性肺部疾病的精确抗炎策略
Vijaya Paul Samuel1, Muhammad Afzal2, M Arockia Babu3
1Department of Anatomy, RAK Medical & Health Sciences University, Ras Al Khaimah College of Medical Sciences, Ras Al Khaimah, United Arab Emirates.
Inflammopharmacology
|December 10, 2025
概括
加斯德明D (GSDMD) 在炎症性肺部疾病中驱动细胞死亡过程 - - 热亡. 向GSDMD通过调节这种细胞死亡途径,为呼吸系统疾病提供了精确的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 肺部病理学 肺部病理学
背景情况:
- 加斯德明D (GSDMD) 是热的主要效应剂,这是一个被编程的细胞死亡途径.
- 热致病导致肺部疾病,如ARDS,COPD,喘和纤维化.
- 激活GSDMD会导致细胞溶解,细胞因子释放和组织损伤.
研究的目的:
- 在炎症性肺部疾病中批判性地审查GSDMD介导的热.
- 分析GSDMD在免疫细胞招募,细胞因子风暴和纤维化中的作用.
- 评估针对GSDMD的新兴治疗干预措施.
主要方法:
- 对2000-2024年研究的文献综述.
- 对临床前疾病模型的分析.
- 对治疗剂的系统评估.
主要成果:
- 在各种肺部疾病中,GSDMD充当了融合性病理调解剂.
- GSDMD激活驱动炎症,免疫细胞透和组织重塑.
- 针对GSDMD的新兴疗法显示出精确干预的前景.
结论:
- GSDMD是急性和慢性炎症性肺部疾病的有希望的治疗点.
- 向GSDMD允许精确调节热致死,而无需广泛的免疫抑制.
- 这种方法为呼吸系统护理提供了新的翻译策略.
相关概念视频
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.0K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.2K
01:26COPD: Management Using Bronchodilators and Corticosteroids
700
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
700
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
436
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
436
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K